Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

µÎ°æºÎÁ¾¾ç ȯÀÚ¿¡¼­ p53ÀÇ °ú¹ßÇö°ú ¹æ»ç¼±Ä¡·á°á°ú P53 Overexpression and Outcome of Radiation Therapy in Head & Neck Cancers

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 1999³â 17±Ç 1È£ p.1 ~ 8
¼Ò¼Ó »ó¼¼Á¤º¸
±èÀÎ¾Æ ÃÖÀϺÀ/°­±â¹®/ÀåÁö¿µ/±è°æ¹Ì/¹Ú°æ½Å/±è¿µ½Å/°­Ã¢¼®/Á¶½ÂÈ£

Abstract

¸ñ Àû : ½ÇÇèÀûÀ¸·Î p53 Á¾¾ç¾ïÁ¦À¯ÀüÀÚ´Â ¼¼Æ÷ÀÇ ¹æ»ç¼±¿¡ ´ëÇÑ ¹ÝÀÀÀ» Á¶ÀýÇÏ´Â °ÍÀ¸·Î
¾Ë·ÁÁ® Àִµ¥, ÀÓ»ó¿¡¼­ p53ÀÇ º¯È­¿Í ¹æ»ç¼±Ä¡·á ÈÄÀÇ ¿¹ÈÄ¿ÍÀÇ »óÈ£°ü·Ã¼ºÀº ¾ÆÁ÷ ¸íÈ®
ÇÏ°Ô ±Ô¸íµÇÁö ¾ÊÀº »óÅÂÀÌ´Ù. ÀÌ¿¡ µÎ°æºÎÁ¾¾çȯÀÚ¿¡¼­ ÈçÈ÷ °üÂûµÇ´Â p53ÀÇ º¯È­°¡ ¹æ»ç
¼±Ä¡·á°á°ú¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´ÂÁö¸¦ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.
Àç·á ¹× ¹æ¹ý : µÎ°æºÎÁ¾¾çÀ¸·Î Áø´ÜµÇ¾î ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº 55¸íÀÇ È¯ÀÚ¸¦ ´ë»ó
À¸·Î ÀÓ»ó°á°ú¸¦ ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù. °¢ ȯÀÚÀÇ Ä¡·áÀü Á¾¾çÁ¶Á÷ÀÇ paraffin sectionÀ»
human p53´Ü¹éÁú¿¡ ´ëÇÑ monoclonal antibody(D-07)·Î ¸é¿ªÁ¶Á÷È­Çп°»öÇÏ¿© labeling
Index (number of labelded nuclei/total number of counted nuclei ¡¿100)¸¦ ±¸ÇÏ¿©, ÀÓ»ó°á
°ú¿Í ¿¬°üÁö¾î ºÐ¼®ÇÏ¿´´Ù.
°á °ú : ÀüüȯÀÚÀÇ 67.2%¿¡¼­ p53ÀÇ ±â´ÉÀÌ»óÀ» ½Ã»çÇÏ´Â °ú¹ßÇö ¼Ò°ßÀ» º¸¿´´Ù. ¿ø¹ßº´
¼Ò¿¡ µû¸¥ °ú¹ßÇö ºóµµ´Â oral cavity, larynx, hypopharynx, nasopharynx¼øÀ¸·Î °¢°¢ 100%,
76%, 67%, 67%, 38%·Î ³ªÅ¸³µ´Ù. Èí¿¬ÀÚ°¡ ºñÈí¿¬ÀÚ¿¡ ºñÇØ À¯ÀÇÇÏ°Ô ³ôÀº °ú¹ßÇö ºóµµ¸¦
º¸¿´´Ù (78.6%, 30.8%). ¿ø¹ßº´¼Ò, º´±â ¹× Karnofsky performance status°¡ ¹æ»ç¼±Ä¡·á¿¡
´ëÇÑ ¹ÝÀÀÀ²°ú À¯ÀÇÇÑ ¿¬°üÀ» º¸¿´À¸¸ç, p53ÀÇ °ú¹ßÇö¿©ºÎ´Â Ä¡·á¹ÝÀÀÀ²¿¡ À¯ÀÇÇÑ ¿µÇâÀ»
¹ÌÄ¡Áö ¸øÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. ¹«º´»ýÁ¸À² ¹× Àüü»ýÁ¸À²¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÎÀÚ´Â ¿ø¹ßº´
¼Ò¿Í º´±â¿´°í, p53ÀÇ °ú¹ßÇö¿©ºÎ´Â À¯ÀÇÇÑ ¿¬°üÀ» º¸ÀÌÁö ¸øÇÏ¿´´Ù.
°á ·Ð : ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº µÎ°æºÎÁ¾¾ç ȯÀÚ¿¡¼­, ¸é¿ªÁ¶Á÷È­Çп°»ö¿¡ ÀÇÇÑ p53ÀÇ
°ú¹ßÇöÀ²Àº ¿ø¹ßº´¼Ò, º´±â ¹× Èí¿¬¿©ºÎ¿Í À¯°üÇÏ¿´À¸¸ç, °ú¹ßÇö¿©ºÎ°¡ Ä¡·á¹ÝÀÀÀ² ¹× »ýÁ¸
À²¿¡ À¯ÀÇÇÑ ¿µÇâÀ» ¹ÌÄ¡Áö ¸øÇÏ¿´´Ù.

Purpose : Experimental studies have implicated the wild type p53 in cellular response
to radiation. Whether altered p53 function can lead to changes in clinical radiocurability
remains an area of ongoing study. This study was performed to investigate whether any
correlation between change of p53 and outcome of curative radiation therapy in patients
with head and neck cancers.
Methods : Immunohistochemical analysis with a mouse monoclonal antibody (D0-7)
specific for human p53 was used to detect to overexpression of protein in formalin fixed,
paraffin-embedded tumor sample from 55 head and neck cancer patients treated with
curative radiation therapy (median dose of 7020 cGy) from February 1988 to March 1996
at 51. Mary's Hospital. Overexpression of p53 was correlated with locoregional control
and survival using Kaplan-Meier method. A Cox regression multivariate analysis was
performed that included all clinical variables and status of p53 expression.
Results : Thirty-seven (67.2%) patients showed overexpression of p53 by
immunohistochemical staining in their tumor. One hundred percent of oral cavity, 76% of
laryngeal, 66.7% of oropharyngeal, 66.7% of hypopharyngeal cancer showed p53
overexpression (P=0.05). The status of p53 had significant relationship with stage of
disease (P=0.03) and history of smoking (P=0.001). The overexpression of p53 was not
predictive of response rate to radiation therapy. The locoregional control was not
significantly affected by p53 stylus. Overexpression of p53 didn't have any prognostic
implication for disease free survival and overall survival. Primary site and stage of
disease were significant prognostic factors for survival.
Conclusions : The p53 overexpression as detected by immunohistochemical staining
had significant correaltion with stage, primary site of disease and smoking habit of
patients. The p53 overexpression didn't have any predictive value for outcome of
curative radiation therapy in a group of head and neck cancers.

Å°¿öµå

p53; ¹æ»ç¼±Ä¡·á; µÎ°æºÎÁ¾¾ç; p53; Radiation therapy; Head & neck cancer;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS